CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression
Journal: OncoTargets and Therapy (2022)
Research Areas: Cancer research
Cell Lines: T98G, U251 (Giloma cells)
Summary: Glioblastoma multiforme (GBM) is a malignant high-grade glioma with a poor clinical outcome. Temozolomide (TMZ) is the first-line GBM chemotherapy, yet patients commonly develop resistance to it. Therefore, the authors investigated the antitumor activity of CAT3 in TMZ-resistant glioblastoma cell lines U251/TMZ and T98G and demonstrated that CAT3 exhibited antitumor activity via blockade of the Hedgehog pathway and enhanced TMZ cytotoxicity in TMZ-resistant GBM.HoloMonitor M4 was used to measure the growth speed of two different TMZ-resistant glioblastoma cells.